Yubo International Biotech Limited (YBGJ)
USD 0.05
(0.0%)
USD 0.05
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2022 | -1.2 Million USD | 21.87% |
| 2021 | -1.54 Million USD | -116.63% |
| 2020 | -711.8 Thousand USD | -380.95% |
| 2019 | -148 Thousand USD | -2.78% |
| 2018 | -144 Thousand USD | 35.71% |
| 2017 | -224 Thousand USD | -72.31% |
| 2016 | -130 Thousand USD | -12.07% |
| 2015 | -116 Thousand USD | -9.43% |
| 2014 | -106 Thousand USD | -2.91% |
| 2013 | -103 Thousand USD | -22.62% |
| 2012 | -84 Thousand USD | 23.64% |
| 2011 | -110 Thousand USD | -27.91% |
| 2010 | -86 Thousand USD | 40.69% |
| 2009 | -145 Thousand USD | -1215.38% |
| 2008 | 13 Thousand USD | 111.4% |
| 2007 | -114 Thousand USD | -26.67% |
| 2006 | -90 Thousand USD | 99.91% |
| 2005 | -101 Million USD | -47995.24% |
| 2004 | -210 Thousand USD | 93.1% |
| 2003 | -3.04 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q1 | -316.93 Thousand USD | -405.9% |
| 2023 Q2 | -367.32 Thousand USD | -15.9% |
| 2022 Q4 | 103.6 Thousand USD | 143.55% |
| 2022 Q3 | -237.92 Thousand USD | 51.6% |
| 2022 FY | -1.2 Million USD | 21.87% |
| 2022 Q1 | -578.96 Thousand USD | -45.77% |
| 2022 Q2 | -491.61 Thousand USD | 15.09% |
| 2021 Q1 | -438.67 Thousand USD | -55.83% |
| 2021 Q2 | -370 Thousand USD | 15.65% |
| 2021 Q3 | -336.58 Thousand USD | 9.03% |
| 2021 Q4 | -397.17 Thousand USD | -18.0% |
| 2021 FY | -1.54 Million USD | -116.63% |
| 2020 Q4 | -281.5 Thousand USD | 7.62% |
| 2020 FY | -711.8 Thousand USD | -380.95% |
| 2020 Q3 | -304.71 Thousand USD | -853.83% |
| 2020 Q2 | -31.94 Thousand USD | 77.33% |
| 2020 Q1 | -140.94 Thousand USD | -314.55% |
| 2019 FY | -148 Thousand USD | -2.78% |
| 2019 Q4 | -34 Thousand USD | 0.0% |
| 2019 Q1 | -33 Thousand USD | 0.0% |
| 2019 Q2 | - USD | 100.0% |
| 2019 Q3 | - USD | 0.0% |
| 2018 Q4 | -33 Thousand USD | 10.81% |
| 2018 FY | -144 Thousand USD | 35.71% |
| 2018 Q3 | -37 Thousand USD | 0.0% |
| 2018 Q1 | -15 Thousand USD | 65.12% |
| 2018 Q2 | - USD | 100.0% |
| 2017 Q2 | - USD | 100.0% |
| 2017 Q3 | -43 Thousand USD | 0.0% |
| 2017 FY | -224 Thousand USD | -72.31% |
| 2017 Q1 | -115 Thousand USD | 0.0% |
| 2017 Q4 | -43 Thousand USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q1 | -30 Thousand USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 FY | -130 Thousand USD | -12.07% |
| 2015 Q1 | -26 Thousand USD | 18.75% |
| 2015 FY | -116 Thousand USD | -9.43% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2014 Q1 | -28 Thousand USD | 0.0% |
| 2014 FY | -106 Thousand USD | -2.91% |
| 2014 Q4 | -32 Thousand USD | -10.34% |
| 2014 Q3 | -29 Thousand USD | 0.0% |
| 2013 Q1 | -26 Thousand USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 FY | -103 Thousand USD | -22.62% |
| 2012 FY | -84 Thousand USD | 23.64% |
| 2012 Q4 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q1 | -19 Thousand USD | 13.64% |
| 2011 Q3 | - USD | 0.0% |
| 2011 FY | -110 Thousand USD | -27.91% |
| 2011 Q1 | -19 Thousand USD | 9.52% |
| 2011 Q4 | -22 Thousand USD | 0.0% |
| 2010 Q4 | -21 Thousand USD | 54.35% |
| 2010 Q1 | -26 Thousand USD | -30.0% |
| 2010 FY | -86 Thousand USD | 40.69% |
| 2010 Q3 | -46 Thousand USD | 0.0% |
| 2009 Q1 | -15 Thousand USD | 0.0% |
| 2009 Q4 | -20 Thousand USD | 0.0% |
| 2009 FY | -145 Thousand USD | -1215.38% |
| 2008 FY | 13 Thousand USD | 111.4% |
| 2008 Q1 | 76 Thousand USD | 0.0% |
| 2007 Q1 | -5000.00 USD | 0.0% |
| 2007 FY | -114 Thousand USD | -26.67% |
| 2006 Q1 | -18 Thousand USD | 0.0% |
| 2006 FY | -90 Thousand USD | 99.91% |
| 2005 Q1 | -100.86 Million USD | 0.0% |
| 2005 FY | -101 Million USD | -47995.24% |
| 2004 FY | -210 Thousand USD | 93.1% |
| 2004 Q1 | 16 Thousand USD | 0.0% |
| 2003 FY | -3.04 Million USD | 0.0% |
| 2003 Q1 | -79 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| American Medical Technologies Inc. | -926.89 Thousand USD | -29.979% |
| Ansell Limited | 76.5 Million USD | 101.575% |
| Ansell Limited | 76.5 Million USD | 101.575% |
| BG Medicine, Inc. | - USD | Infinity% |
| Biotage AB (publ) | 24.28 Million USD | 104.962% |
| BioLife Sciences Inc. | - USD | Infinity% |
| CB Scientific, Inc. | -1.63 Million USD | 26.099% |
| Psykey, Inc. | -1.32 Million USD | 9.002% |
| ConvaTec Group Plc | 130.3 Million USD | 100.925% |
| ConvaTec Group Plc | 130.3 Million USD | 100.925% |
| Encision Inc. | -691.78 Thousand USD | -74.154% |
| Golden Valley Development, Inc | -141.81 Thousand USD | -749.557% |
| Hear AtLast Holdings, Inc. | -234.36 Thousand USD | -414.053% |
| Innovative MedTech Inc. | -7.93 Million USD | 84.825% |
| LifePoint, Inc. | -15.23 Million USD | 92.09% |
| Medite Cancer Diagnostics, Inc. | -6.81 Million USD | 82.311% |
| Paradigm Medical Industries, Inc. | -474 Thousand USD | -154.17% |
| QuantRx Biomedical Corporation | - USD | Infinity% |
| Remedent, Inc. | -274.44 Thousand USD | -338.981% |
| Reflect Scientific, Inc. | -459.02 Thousand USD | -162.46% |
| SmileDirectClub, Inc. | -86.4 Million USD | 98.606% |
| Sector 10, Inc. | 7036.00 USD | 17222.868% |
| Shandong Weigao Group Medical Polymer Company Limited | 2 Billion USD | 100.06% |
| SheerVision, Inc. | -71.37 Thousand USD | -1587.913% |
| United Health Products, Inc. | -2.62 Million USD | 54.074% |
| Vasamed, Inc. | -4.88 Million USD | 75.353% |
| Wearable Health Solutions, Inc. | -2.38 Million USD | 49.559% |